Osprey Medical, Inc. announce the expansion of the company into the Canadian market with Medical Device License (MDL) approval and an exclusive distribution agreement with GE Healthcare Canada Inc. Osprey recently received approval from Health Canada for a Medical Device License (MDL) for the DyeVert Systems. This MDL was approved as the DyeVert technology has positive scientific evidence that supports its quality, safety, and efficacy in reducing Contrast Induced Acute Kidney Injury (CI-AKI). The DyeVert portfolio reduces the amount of contrast dye used in heart imaging procedures and has been proven to reduce CI-AKI by on average 55% without compromising image quality. The MDL approval mirrors the FDA approval process in the US and provides Osprey with the opportunity to distribute in Canada with the approval of Health Canada. Following on from this approval, Osprey has signed an exclusive 4-year distribution agreement with GE Healthcare Canada Inc. for commercialization of the DyeVert System in Canada. This agreement follows the GE Healthcare agreement in Europe, which expanded global commercialisation of Osprey's product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey.